10:10 AM EDT, 03/20/2025 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) filed a registration statement Thursday for the potential sale of up to $400 million of various securities.

The prospectus covers the sale of the company's debt securities, common stock, preferred stock, units and warrants from time to time.

Monte Rosa said it intends to use the net proceeds from the sale of any securities for general corporate purposes, which may include research and development and clinical development costs to support the advancement of its product candidates and the expansion of its research and development programs.

Price: 7.20, Change: +0.50, Percent Change: +7.46